These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 8228729)

  • 1. Influence of endogenous cholinergic tone and alpha-adrenergic pathways on growth hormone responses to His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 in the dog.
    Muruais J; Peñalva A; Dieguez C; Casanueva FF
    J Endocrinol; 1993 Aug; 138(2):211-8. PubMed ID: 8228729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man.
    Peñalva A; Carballo A; Pombo M; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1993 Jan; 76(1):168-71. PubMed ID: 8421084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence that alpha 2-adrenergic pathways play a major role in growth hormone (GH) neuroregulation: alpha 2-adrenergic agonism counteracts the inhibitory effect of muscarinic cholinergic receptor blockade on the GH response to GH-releasing hormone, while alpha 2-adrenergic blockade diminishes the potentiating effect of increased cholinergic tone on such stimulation in normal men.
    Devesa J; Diaz MJ; Tresguerres JA; Arce V; Lima L
    J Clin Endocrinol Metab; 1991 Aug; 73(2):251-6. PubMed ID: 1677361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity.
    Cordido F; Peñalva A; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1993 Apr; 76(4):819-23. PubMed ID: 8473389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.
    Peino R; Cordido F; Peñalva A; Alvarez CV; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1996 Mar; 81(3):909-13. PubMed ID: 8772549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level.
    Popovic V; Damjanovic S; Micic D; Djurovic M; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1995 Mar; 80(3):942-7. PubMed ID: 7883854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E; Di Vito L; Ramunni J; Gianotti L; Giordano R; Deghenghi R; Camanni F; Ghigo E
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of intravenous or intracerebroventricular injections of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 on GH release in conscious, freely moving male rats.
    Yagi H; Kaji H; Sato M; Okimura Y; Chihara K
    Neuroendocrinology; 1996 Feb; 63(2):198-206. PubMed ID: 9053785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
    Cordido F; Peino R; Peñalva A; Alvarez CV; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1996 Mar; 81(3):914-8. PubMed ID: 8772550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6, and pyridostigmine in normal and obese subjects.
    Cordido F; Peñalva A; Peino R; Casanueva FF; Dieguez C
    Metabolism; 1995 Jun; 44(6):745-8. PubMed ID: 7783658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood.
    Micic D; Popovic V; Kendereski A; Macut D; Casanueva FF; Dieguez C
    Clin Endocrinol (Oxf); 1995 Feb; 42(2):191-4. PubMed ID: 7734029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of hypothyroidism, tri-iodothyronine and glucocorticoids on growth hormone responses to growth hormone-releasing hormone and His-D-Trp-Ala-Trp-D-Phe-Lys-NH2.
    Edwards CA; Dieguez C; Scanlon MF
    J Endocrinol; 1989 Apr; 121(1):31-6. PubMed ID: 2497223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The synergistic effects of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 on growth hormone (GH)-releasing factor-stimulated GH release and intracellular adenosine 3',5'-monophosphate accumulation in rat primary pituitary cell culture.
    Cheng K; Chan WW; Barreto A; Convey EM; Smith RG
    Endocrinology; 1989 Jun; 124(6):2791-8. PubMed ID: 2541999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone (GH) responses to the hexapeptide GH-releasing peptide and GH-releasing hormone (GHRH) in the cynomolgus macaque: evidence for non-GHRH-mediated responses.
    Malozowski S; Hao EH; Ren SG; Marin G; Liu L; Southers JL; Merriam GR
    J Clin Endocrinol Metab; 1991 Aug; 73(2):314-7. PubMed ID: 1856262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth hormone-releasing activity of growth hormone-releasing peptide-6 is maintained after short-term oral pretreatment with the hexapeptide in normal aging.
    Ghigo E; Arvat E; Rizzi G; Goffi S; Grottoli S; Mucci M; Boghen MF; Camanni F
    Eur J Endocrinol; 1994 Nov; 131(5):499-503. PubMed ID: 7952160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth hormone (GH) response to GH-releasing peptide-6 in patients with insulin-dependent diabetes mellitus.
    Villas-Boas Weffort RF; Ramos-Dias JC; Chipoch C; Lengyel AM
    Metabolism; 1997 Jun; 46(6):706-10. PubMed ID: 9186309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of sex, age and adrenergic pathways on the growth hormone response to GHRP-6.
    Peñalva A; Pombo M; Carballo A; Barreiro J; Casanueva FF; Dieguez C
    Clin Endocrinol (Oxf); 1993 Jan; 38(1):87-91. PubMed ID: 8435889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral activity of the growth hormone releasing peptide His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 in rats, dogs and monkeys.
    Walker RF; Codd EE; Barone FC; Nelson AH; Goodwin T; Campbell SA
    Life Sci; 1990; 47(1):29-36. PubMed ID: 2117689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of cholinergic tone by pyridostigmine reverses the inhibitory effect of corticotropin-releasing hormone on the growth hormone-releasing hormone-induced growth hormone secretion.
    Corsello SM; Tofani A; Della Casa S; Sciuto R; Rota CA; Colasanti S; Bini A; Barini A; Barbarino A
    Acta Endocrinol (Copenh); 1992 Feb; 126(2):113-6. PubMed ID: 1543015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection.
    Pombo M; Barreiro J; Peñalva A; Peino R; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3180-4. PubMed ID: 7593423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.